Cargando…
The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes
End points that provide an early identification of treatment effects are needed to implement type 1 diabetes prevention trials more efficiently. To this end, we assessed whether metabolic end points can be used to detect a teplizumab effect on rapid β-cell decline within 3 months after treatment in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660991/ https://www.ncbi.nlm.nih.gov/pubmed/34551936 http://dx.doi.org/10.2337/db21-0519 |
_version_ | 1784613305238683648 |
---|---|
author | Sims, Emily K. Cuthbertson, David Herold, Kevan C. Sosenko, Jay M. |
author_facet | Sims, Emily K. Cuthbertson, David Herold, Kevan C. Sosenko, Jay M. |
author_sort | Sims, Emily K. |
collection | PubMed |
description | End points that provide an early identification of treatment effects are needed to implement type 1 diabetes prevention trials more efficiently. To this end, we assessed whether metabolic end points can be used to detect a teplizumab effect on rapid β-cell decline within 3 months after treatment in high-risk individuals in the TrialNet teplizumab trial. Glucose and C-peptide response curves (GCRCs) were constructed by plotting mean glucose and C-peptide values from 2-h oral glucose tolerance tests on a two-dimensional grid. Groups were compared visually for changes in GCRC shape and movement. GCRC changes reflected marked metabolic deterioration in the placebo group within 3 months of randomization. By 6 months, GCRCs resembled typical GCRCs at diagnosis. In contrast, GCRC changes in the teplizumab group suggested metabolic improvement. Quantitative comparisons, including two novel metabolic end points that indicate GCRC changes, the within-quadrant end point and the ordinal directional end point, were consistent with visual impressions of an appreciable treatment effect at the 3- and 6-month time points. In conclusion, an analytic approach combining visual evidence with novel end points demonstrated that teplizumab delays rapid metabolic decline and improves the metabolic state within 3 months after treatment; this effect extends for at least 6 months. |
format | Online Article Text |
id | pubmed-8660991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-86609912022-12-01 The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes Sims, Emily K. Cuthbertson, David Herold, Kevan C. Sosenko, Jay M. Diabetes Pharmacology and Therapeutics End points that provide an early identification of treatment effects are needed to implement type 1 diabetes prevention trials more efficiently. To this end, we assessed whether metabolic end points can be used to detect a teplizumab effect on rapid β-cell decline within 3 months after treatment in high-risk individuals in the TrialNet teplizumab trial. Glucose and C-peptide response curves (GCRCs) were constructed by plotting mean glucose and C-peptide values from 2-h oral glucose tolerance tests on a two-dimensional grid. Groups were compared visually for changes in GCRC shape and movement. GCRC changes reflected marked metabolic deterioration in the placebo group within 3 months of randomization. By 6 months, GCRCs resembled typical GCRCs at diagnosis. In contrast, GCRC changes in the teplizumab group suggested metabolic improvement. Quantitative comparisons, including two novel metabolic end points that indicate GCRC changes, the within-quadrant end point and the ordinal directional end point, were consistent with visual impressions of an appreciable treatment effect at the 3- and 6-month time points. In conclusion, an analytic approach combining visual evidence with novel end points demonstrated that teplizumab delays rapid metabolic decline and improves the metabolic state within 3 months after treatment; this effect extends for at least 6 months. American Diabetes Association 2021-12 2021-09-22 /pmc/articles/PMC8660991/ /pubmed/34551936 http://dx.doi.org/10.2337/db21-0519 Text en © 2021 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license. |
spellingShingle | Pharmacology and Therapeutics Sims, Emily K. Cuthbertson, David Herold, Kevan C. Sosenko, Jay M. The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title | The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title_full | The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title_fullStr | The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title_full_unstemmed | The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title_short | The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes |
title_sort | deterrence of rapid metabolic decline within 3 months after teplizumab treatment in individuals at high risk for type 1 diabetes |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660991/ https://www.ncbi.nlm.nih.gov/pubmed/34551936 http://dx.doi.org/10.2337/db21-0519 |
work_keys_str_mv | AT simsemilyk thedeterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT cuthbertsondavid thedeterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT heroldkevanc thedeterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT sosenkojaym thedeterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT simsemilyk deterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT cuthbertsondavid deterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT heroldkevanc deterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes AT sosenkojaym deterrenceofrapidmetabolicdeclinewithin3monthsafterteplizumabtreatmentinindividualsathighriskfortype1diabetes |